top of page
Benefits and risks associated with different uses of the COVID-19 vaccine Vaxzevria
Full title: Benefits and risks associated with different uses of the COVID-19 vaccine Vaxzevria: a modelling study, France, May to...
Jun 30, 2021
Lockdown as a last resort option in case of COVID-19 epidemic rebound: a modelling study
Euro Surveill Tran Kiem C, Crépey P, Bosetti P, Levy Bruhl D, Yazdanpanah Y, Salje H, Boëlle PY, Cauchemez S BackgroundGiven its high...
May 31, 2021
Lessons learned from the investigation of a COVID-19 cluster in Creil, France
BMC Infectious Diseases De Laval F, Grosset-Janin A, Delon F, Allonneau A, Tong C, Letois F, Couderc A, Sanchez A, Destanque, Biot F,...
May 18, 2021
Inhibition of the replication of SARSCoV-2 in human cells by the FDA-approved drug chlorpromazine
Int J Antimicrob Agents Plaze M, Attali D, Prot M, Petit AC, Blatzer M, Vinckiera F, Levillayer L, Chiaravalli J, Perin-Dureau F, Cachiai...
Mar 1, 2021
Covid-19: Keeping schools as safe as possible
British Medical Journal Arnaud Fontanet, Rebecca Grant, Margrethe Greve-Isdahl, Devi Sridhar. A year into the pandemic, and confronted...
Feb 24, 2021
Lockdown impact on COVID-19 epidemics in regions across metropolitan France
Published in The Lancet Simon Cauchemez, Cécile Tran Kiem, Juliette Paireau, Patrick Rolland, Arnaud Fontanet Lockdowns have been used by...
Sep 28, 2020
Estimating the burden of SARS-CoV-2 in France
Science Henrik Salje, Cécile Tran Kiem, Noémie Lefrancq, Noémie Courtejoie, Paolo Bosetti, Juliette Paireau, Alessio Andronico,...
Jul 9, 2020
Introductions and early spread of SARS-CoV-2 in France, 24 January to 23 March 2020
Euro Surveill Gámbaro F, Behillil S, Baidaliuk A, Donati F, Albert M, Alexandru A, Vanpeene M, Bizard M, Brisebarre A, Barbet M, Derrar...
Jul 1, 2020
Cluster of COVID-19 in northern France: A retrospective closed cohort study
MedRXiv Arnaud Fontanet, Laura Tondeur, Yoann Madec, Rebecca Grant, Camille Besombes, Nathalie Jolly, Sandrine Fernandes Pellerin,...
Apr 22, 2020
bottom of page
